The oral pathogen Porphyromonas gingivalis gains tolerance to the antimicrobial peptide DGL13K by synonymous mutations in hagA

Porphyromonas gingivalis is a keystone pathogen for periodontal disease. The bacteria are black-pigmented and require heme for growth. P . gingivalis exhibit resistance to many antimicrobial peptides, which contributes to their success in the oral cavity. P . gingivalis W50 was resistant to the anti...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 19; no. 10; p. e0312200
Main Authors Gorr, Sven-Ulrik, Chen, Ruoqiong, Abrahante, Juan E., Joyce, Paul B. M.
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 24.10.2024
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0312200

Cover

More Information
Summary:Porphyromonas gingivalis is a keystone pathogen for periodontal disease. The bacteria are black-pigmented and require heme for growth. P . gingivalis exhibit resistance to many antimicrobial peptides, which contributes to their success in the oral cavity. P . gingivalis W50 was resistant to the antimicrobial peptide LGL13K but susceptible to the all-D-amino acid stereoisomer, DGL13K. Upon prolonged exposure to DGL13K, a novel non-pigmented mutant was isolated. Exposure to the L-isomer, LGL13K, did not produce a non-pigmented mutant. The goal of this study was to characterize the genomic and cellular changes that led to the non-pigmented phenotype upon treatment with DGL13K. The non-pigmented mutant showed a low minimum inhibitory concentration and two-fold extended minimum duration for killing by DGL13K, consistent with tolerance to this peptide. The DGL13K-tolerant bacteria exhibited synonymous mutations in the hagA gene. The mutations did not prevent mRNA expression but were predicted to alter mRNA structure. The non-pigmented bacteria were deficient in hemagglutination and hemoglobin binding, suggesting that the HagA protein was not expressed. This was supported by whole cell enzyme-linked immunosorbent assay and gingipain activity assays, which suggested the absence of HagA but not of two closely related gingipains. In vivo virulence was similar for wild type and non-pigmented bacteria in the Galleria mellonella model. The results suggest that, unlike LGL13K, DGL13K can defeat multiple bacterial resistance mechanisms but bacteria can gain tolerance to DGL13K through mutations in the hagA gene.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: SUG holds three patents related to the research reported in this manuscript: Synthetic peptides and peptide mimetics. U.S. Patent number: US9914750. Date of Patent: March 13, 2018. Assignee: University of Louisville Research Foundation Inventor: Sven-Ulrik Gorr. Synthetic peptides and peptide mimetics. U.S. Patent number: US8569449, Date of Patent: October 29, 2013, Assignee: University of Louisville Research Foundation. Inventor: Sven-Ulrik Gorr. Peptides, hydrogel compositions and methods of use thereof. U.S. Patent number: US12037374. Date of Patent: July 16, 2024, Assignee: Regents of the University of Minnesota. Inventors: S.-U. Gorr, C. Aparicio and Z. Ye. SUG is Chief Scientific Officer and holds equity in Gavia BIO, LLC, which is developing the antimicrobial peptide DGL13K. These interests have been reviewed and managed by the University of Minnesota in accordance wit its Conflict of interest policies. The other authors declare no commercial funding, employment, consultancy, or commercial products in development related to these patents. This does not alter our adherence to PLoS ONE policies on sharing data. Mutant strains of P. gingivalis, developed in this research, are available from the University of Minnesota upon completion of a Materials Transfer Agreement
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0312200